KRAS and cancer: Although Tipifarnib, as seen with other FTIs, can have effects not only on RAS GTPases, but also on other proteins such as HDJ-2, CENPE, PRL65–67, Tipifarnib seems to be quite an efficient therapeutical approach against hyperactive HRAS-driven cancers32,68,69 and in KRAS-driven cancers in combination with KRAS G12C inhibitors70.